Y - Posted a gain today with lighter volume, rebounding near its pivot point. Thinly traded Biomed/Biotech firm was covered in greater detail in the 1/18/19 FSU analysis with an annotated graph.
Y - Ended near the session low with a big loss today breaking a streak of 4 consecutive gains. Highlighted in yellow with pivot point cited based on its 11/07/18 high plus 10 cents in the 1/18/19 mid-day report. Thinly traded Biomed/Biotech firm's earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies. See the latest FSU analysis for more details and an annotated graph.
Y - Finished in the lower third of its intra-day range after highlighted in yellow with pivot point cited based on its 11/07/18 high plus 10 cents in the earlier mid-day report. Thinly traded Biomed/Biotech firm hit a new 52-week high and posted 4 consecutive gains marked by volume. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies. See the latest FSU analysis for more details and a new annotated graph.
Y - Color code is changed to yellow with pivot point cited based on its 11/07/18 high plus 10 cents. Thinly traded Biomed/Biotech firm hit a new 52-week high on the prior session with its twice average volume, and it is on track today for a 4th consecutive gain on ever-increasing volume. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is hitting a new 52-week high with today's 3rd consecutive gain on ever-increasing volume. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is challenging its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating near its 50 DMA line and perched near its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating near its 50 DMA line and perched near its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating near its 50 DMA line and perched near its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating near its 50 DMA line and perched near its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating above its 50 DMA line and perched near its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating above its 50 DMA line and perched near its 52-week high. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is consolidating near its 50 DMA line. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is rebounding near its 50 DMA line. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Thinly traded Biomed/Biotech firm is challenging its 52-week high with today's gap up gain. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule in the context of all publicly traded companies.
Challenged its 52-week high with today's early gain. Earnings increases have been above the +25% minimum guideline (C criteria) in the 4 latest quarterly comparisons through Sep '18. Sales revenues growth showed acceleration, but quarterly totals have been in the $7-8 million range, still rather minuscule.
Again rebounding above its 50 DMA line toward its 52-week high. Noted with caution in prior mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Rebounding above its 50 DMA line toward its 52-week high. Noted with caution in prior mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Pulling back from its 52-week high, slumping toward its 50 DMA line ($59.47). Noted with caution in prior mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Perched at its 52-week high following gains marked by above average volume. Found support above its 50 DMA line while consolidating since noted with caution in the 9/13/18 mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Perched at its 52-week high with today's 3rd consecutive gain. Recent gains were marked by above average volume. Found support above its 50 DMA line while consolidating since noted with caution in the 9/13/18 mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Hit another new 52-week high today. Recent gains were marked by above average volume. Found support above its 50 DMA line while consolidating since noted with caution in the 9/13/18 mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Perched at its 52-week high with today's 4th consecutive gain marked by increasing volume. Found support above its 50 DMA line while consolidating since last noted in the 9/13/18 mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Powering to a new 52-week high with today's gain marked by heavier volume, adding to a recent spurt. Noted in prior mid-day reports - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Powering to a new 52-week high with today's 5th consecutive gain marked by heavier volume. Noted in prior mid-day report - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Powering to a new 52-week high with today's 3rd consecutive gain withh ever-increasing volume. Noted in prior mid-day report - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Perched near its 52-week high following considerable volume-driven gains. Last noted in the 8/16/18 mid-day report - "Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons."
Perched near its 52-week high following considerable volume-driven gains. Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons.
Abruptly reversed into the red after an early gain today following a considerable volume-driven gain on the prior session. Fundamental concerns remain. Earnings increases have not been strong and steady above the +25% minimum guideline (C criteria) in quarterly comparisons.
Consolidating near its 50 DMA line. Prior mid-day reports cautioned - "Fundamental concerns remain. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '16."
Rebounding above its 50 DMA line with a volume-driven gain today. Prior mid-day reports cautioned - "Fundamental concerns remain. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '16."
Slumped below the 50 DMA line with volume-driven losses since the 3/17/17 mid-day report cautioned - "Fundamental concerns remain. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '16."
The 3/17/17 mid-day report cautioned - "Fundamental concerns remain. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '16."
Fundamental concerns remain. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '16.
Hit another new high today following considerable volume-driven gains. Prior mid-day reports cautioned members - "Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14."
Hit another new high today following a considerable volume-driven gain on the prior session, breaking out of a tight range. Following a "negative reversal" on 6/23/15, prior mid-day reports repeatedly cautioned members - "Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. While testing support at its 200 DMA line, it was noted with caution in the 4/28/15 mid-day report - 'Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.'"
Holding its ground in a tight range following a "negative reversal" on 6/23/15 at its 52-week high. Prior mid-day reports cautioned members - "Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. While testing support at its 200 DMA line, it was noted with caution in the 4/28/15 mid-day report - 'Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.'"
Holding its ground since last noted with caution in the 6/23/15 mid-day report after a "negative reversal" at its 52-week high - "Held its ground following a technical breakout and impressive volume-driven gains. Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. While testing support at its 200 DMA line, it was noted with caution in the 4/28/15 mid-day report - 'Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.'"
Reversed into the red after touching another new 52-week high today. Held its ground following a technical breakout and impressive volume-driven gains. The 6/02/15 mid-day report last cautioned members - "Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. While testing support at its 200 DMA line, it was noted with caution in the 4/28/15 mid-day report - 'Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.'"
Stubbornly holding its ground near its 52-week high following a technical breakout and impressive volume-driven gains last week. Prior mid-day reports cautioned members - "Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. While testing support at its 200 DMA line, it was noted with caution in the 4/28/15 mid-day report - 'Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.'"
Technically, it broke out on 5/27/15 and hit new 52-week highs with impressive volume-driven gains this week. Reported greatly improved sales revenues and earnings for the Mar '15 quarter, but fundamental concerns remain. While testing support at its 200 DMA line, it was noted with caution in the 4/28/15 mid-day report - "Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14."
Technically, it broke out on the prior session and it hit another new 52-week high with today's 6th consecutive gain marked by volume. While testing support at its 200 DMA line, it was last noted with caution in the 4/28/15 mid-day report - "Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14."
Testing its 200 DMA line with today's 3rd consecutive volume-driven loss. Repeatedly noted with caution in recent mid-day reports - "Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14."
Consolidating below its 50 DMA line and above its 200 DMA line. Last noted with caution in the 4/13/15 mid-day report - "Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14."
Consolidating near its 50 DMA line and perched within striking distance of its 52-week high. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.
Consolidating near 50 DMA and within striking distance of its 52-week high. Earnings increases have been below the +25% minimum guideline (C criteria) in quarterly comparisons through Dec '14.